Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03353051
Other study ID # SCC1525
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 25, 2017
Est. completion date April 3, 2019

Study information

Verified date February 2020
Source London School of Hygiene and Tropical Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The motivation for this study was produced from our preliminary data, which showed that during the first 96 hours of life a full-term neonate will actively reduce the overall serum iron concentration of their blood and the transferrin saturation decreases rapidly from 45% in cord blood to ~20% by six hours post-delivery.

The Investigators hypothesise that this active sequestration of iron, which results in hypoferremia, is done in an effort to limit susceptibility to infection, a process referred to as nutritional immunity.

Currently, little is known about iron regulation and iron homeostasis during the first week of life and even less is known about the comparisons of nutritional immunity between full term, preterm and low birth weight neonates. Additionally, limited research has been conducted on the impact of these processes on bacterial pathogens.

In an effort to study the neonatal nutritional immunity and its role in neonatal susceptibility to infection, The investigator will conduct an observational study in full-term, preterm and low birth weight vaginally-delivered neonates born at Serrekunda General Hospital, The Gambia.

The investigators will fully characterise and quantify nutritional immunity during the early neonatal period and the investogators will assess how this impacts bacterial growth. Study sensitisation will occur at the antenatal clinic, during the mother's second trimester of pregnancy. Mothers will be consented and enrolled at delivery. Blood samples will be collected once from the umbilical cord and at serial time points from the neonates over the first week of life.


Description:

The epicentres of neonatal death worldwide are West and Central Africa, with an estimated 35 deaths per 1000 births. Neonatal infection is the third largest cause of death in children under five worldwide and is an ongoing major global public health challenge (WHO Millennium Development Goal 4). Intrauterine and neonatal infections have a high risk of causing substantial long-term neurological morbidity, affecting not just the individual but the local community and national productivity. Current research on neonatal sepsis in low-resource settings is focused on the use of mass perinatal antibiotic therapy for both mothers and babies. However, antibiotic resistance in the developing world is dramatically increasing and ablation of the neonatal microbiome has been linked with long-term health consequences. Novel therapeutic solutions are urgently required.

Nutritional immunity is the process by which the host innate immune system limits nutrient availability to invading organisms. Iron is an essential micronutrient for both microbial pathogens and their mammalian hosts. Changes in iron availability and distribution have significant effects on pathogen virulence and on the immune response to infection. Commonly found in blood, iron and its moieties (heme) are sequestered mainly in chaperone molecules (transferrin, lactoferrin, haptoglobin, hemopexin). The long-term goal of our research is to develop an anti-virulence therapeutic strategy that will augment nutritional immunity in the at-risk newborn, in order to improve neonatal survival, while avoiding the use of traditional empirical antibiotics.

During the dynamic neonatal period there are significant changes in circulation, oxygenation and iron homeostasis, the foetus maintains a high haematocrit to facilitate perfusion in utero. Within the first week of life, the neonate's haematocrit decreases as the RBCs containing foetal haemoglobin are broken down. Our preliminary data shows that during the first 24 hours of life full-term neonates will actively reduce the overall serum iron concentration and transferrin saturation decreases rapidly from 45% in cord blood to ~20% by six hours post-delivery.

Currently, little is known about nutritional immunity in the neonates or about its impact on bacterial pathogens. In the aims below, the investigators will investigate the hypothesis that nutritional immunity may be an evolutionary mechanism designed to protect neonates from infection during the first critical days of life, by limiting the pathogenicity and virulence of these organisms by reducing the availability of iron. The investigators hypothesize that this protective mechanism may not be activated in preterm and low birth weight neonates, putting these babies at an enhanced risk of neonatal infection.

Host chaperoned or unchaperoned iron, hemoglobin and heme in the blood can provide a growth-limiting nutrient to bacterial pathogens depending on the specific bacterial species and their iron-uptake mechanisms. Bacterial co-evolution with the host has resulted in two main strategies to combat host nutritional immunity: (1) chelation of iron away from chaperone proteins with siderophores, and (2) direct uptake of hemoglobin and heme moieties. Previous research and preliminary experiments conducted by our group, using ex-vivo growth assays in adult serum, has shown that growth of a panel of neonatal pathogenic bacteria each decreases in response to decreasing transferrin saturation and increases in response to increasing hemoglobin concentration. In addition, the investigators have shown that the in vitro growth of standard laboratory strains of four important causes of early neonatal sepsis in the developing world (Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, and Streptococcus agalactiae) is decreased in hypoferremic serum collected from full term neonates between 6-24 hours after birth compared to serum from the umbilical cord at birth.

In an effort to study neonatal nutritional immunity and its role in neonatal susceptibility to infection, the investigators will conduct an observational study in full-term (FT), preterm (PTB) and low birth weight (LBW) vaginally-delivered neonates born at Serrekunda Hospital in The Gambia. The investigators will fully characterize and quantify nutritional immunity during the early neonatal period (Research Question 1, Research Question 2 and Research Question 3) and the investigators will assess how it impacts bacterial growth using in vitro assays (Research Question 4). Mothers will be consented and enrolled at delivery. Blood samples will be collected once from the umbilical cord and at serial time points from the neonates (see sampling schema).


Recruitment information / eligibility

Status Completed
Enrollment 430
Est. completion date April 3, 2019
Est. primary completion date November 21, 2018
Accepts healthy volunteers
Gender All
Age group N/A to 28 Days
Eligibility Inclusion Criteria:

Low Birth Weight (LBW) neonates:

- Medical stable neonates

- Neonatal weight =2000g and <2500g

- Born at Serrekunda Hospital

- Gestational age will be >37 weeks.

- Born to mothers at least 18 years of age

Preterm neonates with Low Birth Weight (PTB+LBW):

- Medical stable neonates

- Born at Serrekunda Hospital

- Neonates weighing <2500g and <37 weeks of gestational age.

- Born to mothers at least 18 years of age

Preterm (PTB) neonates:

- Medical stable neonates

- >32 and <37 weeks' gestational age

- Born at Serrekunda Hospital

- PTB neonates will weigh more than 2500g

- Born to mothers at least 18 years of age

Full Term (FT) neonates:

- Healthy neonates

- Born at Serrekunda Hospital

- FT neonates will weigh =2500g

- Gestational age =37 weeks

- Born to mothers at least 18 years of age

Exclusion Criteria:

- Major congenital malformations

- Severe birth asphyxia

- Children from multiple births

- Medication (i.e. prophylactic antibiotics) given to neonate before first neonatal venous blood draw

- Neonates born via Breech, Vacuum or C section

- Neonates with infection/illness (information gained from venous bleed) will no longer be required to give future samples if originally required

Study Design


Intervention

Other:
Observational study
Observational study

Locations

Country Name City State
Gambia Serrekunda General Hospital Kanifing Near Banjul

Sponsors (3)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine Department of State for Health and Social Welfare, The Gambia, University of Oxford

Country where clinical trial is conducted

Gambia, 

Outcome

Type Measure Description Time frame Safety issue
Primary serum iron will be measured using a COBAS INTEGRA 400 plus clinical chemistry analyzer at 7 days after birth
Secondary TSAT (%) and heme iron (mg/dL) During the neonatal transition period in PTB and LBW neonates and FT babies in cord blood and at 6 hours after birth. TSAT and heme iron will be measured using a using a COBAS INTEGRA 400 plus clinical chemistry analyzer . at 6 hours after birth
Secondary Iron (ug/dL), TSAT (%) and heme iron (mg/dL) regulated regulation in FT neonates During the first 7 days of life. Iron, TSAT and heme iron will be measured using a using a COBAS INTEGRA 400 plus clinical chemistry analyzer 7 days after birth
Secondary microorganisms that are common causes of neonatal sepsis Does sera from PTB and LBW neonates after birth support more ex-vivo growth of microorganisms that are common causes of neonatal sepsis in Africa and The Gambia (Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Group B Streptococcus, Streptococcus pneumoniae and Salmonella Tyhpimurium) than sera from FT neonates At 0, 6 and 24 hours after birth
See also
  Status Clinical Trial Phase
Completed NCT04200807 - Non-invasive Measurement of Neonatal Central and Peripheral Hemodynamics
Recruiting NCT05695196 - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant Phase 1
Completed NCT01729000 - Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis N/A
Completed NCT06413056 - Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection Phase 4
Completed NCT03247920 - Reduction of Intravenous Antibiotics In Neonates Phase 4
Completed NCT02486783 - Infection, Sepsis and Meningitis in Surinamese Neonates N/A
Recruiting NCT06194396 - Effect of Chlorhexidine Versus Alcohol on Infections in Neonates N/A
Active, not recruiting NCT05343403 - Parental Participation on the Neonatal Ward - the neoPARTNER Study
Recruiting NCT04416373 - COVID-19 and Pregnancy Outcomes
Completed NCT01540162 - Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement N/A
Withdrawn NCT03673566 - Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO N/A
Completed NCT04883801 - Clinical Outcomes of Newborns Born to Pregnant Women With and Without COVID-19
Terminated NCT05379452 - Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai
Active, not recruiting NCT04718220 - Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19 N/A
Not yet recruiting NCT06102044 - Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania Phase 3
Active, not recruiting NCT04433364 - COPE - COVID-19 in Pregnancy and Early Childhood
Completed NCT03383211 - Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Completed NCT04893343 - Antibiotic Use in a Neonatal Intensive Care Unit Practicing Integrative Medicine
Withdrawn NCT03673579 - Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB N/A
Completed NCT04206878 - Evaluating the Feasibility of Point of Care Birth Testing in Eswatini